Strategies for Maximizing Outcomes in Liver Transplantation James D. Eason, M.D. Chief of Transplantation / Professor of Surgery University of Tennessee.

Slides:



Advertisements
Similar presentations
Liver Transplant Outcomes in the United States : Effect of Preservation Solution DKFC Symposium July 16, 2012 John Fung, MD, PhD Cleveland Clinic Disclosure:
Advertisements

Supporting the Neonatal and Pediatric Donor Breakout Session A Presenters: Jeffrey Johnson, MD, LAC + USC Medical Center Mudit Mather, MD, Loma Linda University.
Northwestern University Feinberg School of Medicine New Trends in organ donation and Transplantation Juan Carlos Caicedo, MD FACS Director, Hispanic Transplant.
Prolonged Diabetes Reversal after intraportal xenotransplantation of wild-type porcine islets in immunosuppressed nonhuman primates Hering et al, Nature.
Superior outcomes in HIV-positive kidney transplant patients compared to HCV-infected or HIV/HCV co-infected recipients Deirdre Sawinski MD, Kimberly A.
What makes a pancreas allograft marginal? Peter J Friend University of Oxford.
Impact of expanded criteria donors on patient survival after heart, lung, liver and combined organ transplantation Quebec experience from 2003 to 2009.
Donor Utilization: Making Use of a Precious Resource in Cardiac Transplant Jason W. Smith, MD Assistant Professor of Surgery The University of Washington.
Practical Protocols – experience and evidence based routines Henrik Ekberg.
Horizon Scanning on organ perfusion
Facing the Organ Shortage Crisis: Business as Usual vs Non- Conventional Solutions? Richard Perez MD Division of Transplant Surgery UC Davis Medical Center.
Australian States Number of Donors Per Million Population Aust * NSW population excludes residents of the NSW Southern Area.
© ANZOD Registry Australian States Number of Donors Per Million Population Aust * NSW population excludes residents of the.
Organ Preservation with Histidine-Tryptophan- Ketoglutarate (HTK) Solution with an Emphasis on Non-Heart Beating Donors (NHBD) John J. Fung, M.D., Ph.D.
Organ Donation in DCD: 10 Year Experience at the University of Michigan A Rojas-Pena, MD; L Sall, BS; K. Koch, BS; E Cooley, RN; M Gravel, RN; R Bartlett,
David C. Mulligan, MD, FACS
Comparison of HTK and UW in Abdominal Transplantation Dr. Richard S. Mangus, MD MS Indiana University, School of Medicine.
Tolerance Induction after Kidney Transplantation Stephan Busque MD M Sc FRCSC Director, Adult Kidney and Pancreas Transplantation Program Stanford University.
Short and Long term function and survival of other graft harvested as part of a multiorgan procurement including the intestine Farinelli P, Troncoso J,
INFLUENCE OF HLA MISMATCH ON GRAFT SURVIVAL IN RENAL TRASPLANTATION IN ADULTS IN ARGENTINA Bisigniano Liliana MD., López-Rivera Arturo MD., Tagliafichi.
LIVER TRANSPLANTATION- BASICS IN SURGERY
+ Liver Transplantation for PSC Patients A Transplant Surgeon’s Perspective Tiffany Anthony, MD Annette C. and Harold C. Simmons Transplant Institute Baylor.
Ex Vivo Lung Perfusion with Adenosine A2A Receptor Agonist Decreases Ischemia-Reperfusion Injury in Donation after Cardiac Death CE Wagner, NH Pope, EJ.
Experience with Calcineurin Inhibitor-Free Immunosuppression in Kidney Transplantation with Marginal Donors Oppenheimer F, Saval N, Gutierrez A, Cam pistol.
Hepatitis C+ Recipients: Considerations for Exclusion Emily A. Blumberg, M.D.
Study of cytokine gene polymorphism and graft outcome in live-donor kidney transplantation By Rashad Hassan MD Amgad El-Agroudy, Ahmad Hamdy, Amani Mostafa.
Monthly Journal article review: Vimmi Kang PGY 2
Severe vascular lesions and poor functional outcome
Donation after circulatory death (DCD) liver transplantation (LT) has been introduced to partially overcome the organ donor shortage DCD LT has lower graft.
Region 10 and In situ Split of the Deceased Donor Liver OSOTC Education Conference September 11, 2015.
TRANSPLANTATION CHAPTER 8 ANZDATA Registry Annual Report 2013.
RAPAMUNE ® TM 1 Randomization Variable Day* to Day 386 Randomization Variable Day* to Day 386 RAPA, C min, TN0.765 CsA, C min, TN0.201 Gender0.117 Increasing.
Liver and Intestinal Organ Transplantation Committee Update Report David Mulligan, MD, Chair OPTN/UNOS Board of Directors Meeting November 12-13, 2014.
3 Patrick T Anderson, 2,3 Vivian McAlister, 1,3 Alp Sener, 1,3 Patrick P Luke Divisions of 1 Urology and 2 Surgery, Department of Surgery, 3 Schulich School.
CR-1 Everolimus Benefit/Risk Assessment Howard J. Eisen, MD Thomas J. Vischer Professor of Medicine Chief, Division of Cardiology Drexel University College.
HEART TRANSPLANTATION Pediatric Recipients 2014 JHLT Oct; 33(10):
Andreas A. Rostved, MD Research assistant Department of Surgical Gastroenterology and Transplantation Rigshospitalet – Copenhagen University Hospital Denmark.
A CRITICAL ANALYSIS OF ORGAN PERFUSION SOLUTIONS IN LIVER TRANSPLANTATION John J. Fung, MD Director, Cleveland Clinic Health System Center for Transplantation.
Successful Multivisceral plus Kidney Transplantation of a highly sensitised paediatric recipient; with Eculizumab salvage for hyperacute renal rejection.
Transplantation in HIV+ Recipients Ron Shapiro, M.D. THOMAS E. STARZL TRANSPLANTATION INSTITUTE UNIVERSITY OF PITTSBURGH.
Open-label W24 ≥ 18 years Chronic HCV infection All genotypes HCV RNA ≥ 10,000 IU/ml Liver transplantation months earlier Child Pugh ≤ 7 and MELD.
RAD Immunosuppression in Heart Transplant Recipients Duke Heart Failure Research Pager:
Impact of Recipient and Donor Non-immunological factors on the Outcome of Expanded Criteria Deceased Donors Kidney Transplantation Dr Hajar Al Hayyan.
Therapeutic Hypothermia in Deceased Organ Donors and Kidney-Graft Function R3 김동연 /Prof. 정경환 N Engl J Med 373;5 July 30, 2015.
Thymoglobulin: An Overview of Its Performance in Clinical Trials as an Agent for the Induction Therapy Reference: Osama Gaber A, Knight RJ, Patel S, et.
Liver transplantation for HCV infection R3 양 인 호 /Prof 김 병 호.
Influence of Back Table Portal and Arterial Flushing with HTK and Tacrolimus on the Incidence of Liver Graft Dysfunction P-702 A Shcherba 1, A Minou 2,
United States Organ Transplantation SRTR & OPTN Annual Data Report, 2011 Kidney.
Cadaveric vs Living Donation; Comparing Options
Acute Liver Failure Anand Annamalai.
Living Donor Transplants
LOMR Portal Project Chris Marsh MD, FACS, Project Lead
Kidney Transplantation.
HCV & liver transplantation
Relationship between Mixed Chimerism and Clinical Tolerance after Combined Kidney and Hematopoietic Cell Transplantation using Total Lymphoid Irradiation.
Nalaka Gunawansa, John McCall, Stephen Munn, Peter Johnston
Number of Grafts Performed by Country
Volume 61, Issue 3, Pages (September 2014)
C. Chalklin, C. Colmont, A. Zaidi, J. Warden-Smith, E. Ablorsu
Liver Transplantation: 50 years
Liver only transplants in the UK Question 2: In terms of survival benefit.
Left ventricular dilatation, the presence of intra-cardiac thrombus and short term outcome for primary heart graft failure patients managed with ECMO.
Monthly Journal article review: Vimmi Kang PGY 2
The incidence of all cause graft failure, and death with a functioning graft was higher in patients who received a DCD donor transplant with total donor.
Number of Donors in Australia
Number of Donors in Australia
Robert J. Porte, MD, PhD Professor of Surgery
Presentation transcript:

Strategies for Maximizing Outcomes in Liver Transplantation James D. Eason, M.D. Chief of Transplantation / Professor of Surgery University of Tennessee / Methodist Transplant Institute

Recent Publications (HTK) is associated with reduced graft survival in deceased donor livers, especially those donated after cardiac death. Stewart ZA, Cameron AM, Singer AL, Montgomery RA, Segev DL. Am J Transplant Feb;9(2):

Results All deceased donor transplants (n = 4755 HTK and UW) HR 1.14 (1.05–1.23) p = Donor after cardiac death (n = 254 HTK and 575 UW) HR1.44 (1.05–1.97) p = 0.025

Problems Extended Criteria donors Age Steatosis DCD Ischemia Reperfusion Injury Cold and warm ischemia Cell Death over time Immunosupression Minimizing adverse events

UT Experience 120 Liver Transplants in th Largest in US 401 Cadaveric OLT over 40 months 24 DCD HTK perfusion in 90% of donors RATG induction Steroid-free immunosuppression

National Results PatientGraft United States University of TN/Methodist Cleveland Clinic Indiana- Clarian Johns Hopkins

Ischemia-Reperfusion HTK - Low viscosity Buffered- minimize drop in pH Biliary protective Endothelial protective

Timing is Everything! Cold Ischemic Time Usually under 6 hours Anastomotic time Reperfusion Arterialization Warm Ischemic time in DCD Rapid Cannulation

Immunosuppression RATG Induction May decrease immune contribution to ischemia- reperfusion

Results 9 th largest program in adult OLT over 40 months 20 combined liver/kidney Age at Transplant52.8 ± 9.42 years Male Recipient73.3% Caucasian Recipient72.4% MELD Score22 ± 4.89

A Matter of Time Warm Ischemic Time (anastomotic) 36.8 ± 11.9 minutes Cold Ischemic Time5.7 ± 2.2 hours Arterialization - 60 minutes Mean operative time 4 hours (2.1 – 6)

DCD results 24 DCD OLT over 3 years Mean F/U – 450 days 20 patients > 1 year 91% one -year patient survival 2 deaths within one year 1sepsis, 1 PNF 1 death at 13 months - heart failure 2 patients with intrahepatic strictures two years post-transplant

DCD MELD -median 18 (15-22) Donor age mean- 35years (15-52) Cannulation time – 2minutes Warm Ischemic time - (7-42 minutes)pressure / O2 sat < 80 Cold ischemic time hours ( ) Anastomotic time - mean 32 minutes

DCD deaths

DCD protocol Staff surgeon – experience matters HTK Minimize times WIT Cannulation CIT arterialization Donor selection Proper recipient selection

Immunosuppression Protocol RATG 1.5 mg/kg in anhepatic phase and POD 2 – total 3mg/kg Premedication -500 mg methylprednisolone, 500 mg acetominophen and 25mg diphenhydramine MMF 1gram BID on Day 1 Tacrolimus begun on day 2 or when serum creatinine fell below 2mg/dl Primary sirolimus if serum creatinine > 2.5 or oliguric by Day 7

Immunosuppression (continued) Tacrolimus target level Day 7-12 weeks weeks months3 After 12 months1-3

Tacrolimus Initiation Mean days Range 2 – 12 days 27 patients started day 4 – 12 7 subsequently converted to sirolimus Mean tacrolimus levels Day Day

Serum Creatinine Liver Transplant Recipients only (n= 101) Time Post-Transplantp<.001 for all time points from pretransplant P < (for all time points)

Tacrolimus levels Day 71 month3 months6 monthsOne year

Sirolimus 40 patients started on primary sirolimus therapy within 15 days 25 additional patients converted after 30 days

Minimal Immunosuppression Single agent Tacrolimus Sirolimus Continue weaning to lowest levels

Maximizing Outcomes Control controllable factors Ischemic time Preservation solution- HTK Proper selection/ matching ofdonor – recipient Minimize immunosuppression to avoid complications

Conclusion Excellent outcomes that exceed expected survival can be achieved with HTK preservation when performed by experienced surgeons under controlled circumstances